Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Zonagen (zona) - good buy? -- Ignore unavailable to you. Want to Upgrade?

To: Hank who wrote (4653)	7/1/1998 12:03:00 AM
From: Linda Kaplan	Respond to of 7041

That's true. I had a Mexican assistant for some time and she informed me it's that way all through the country. It has not changed with the times. But I don't think anyone took the approval in Mexico to mean anything about the value of the drug. Do you? The important filing hasn't even been made yet. It seems to me that if the company is legitimate, expecting to obtain US approval, that the focus should be on that at this point. The rationale for Mexico is that there were trials there so it was a relatively quick and easy approval. No rigorous proofs were necessary there, though even so, Claud was saying they were approved in Mexico a year before they were. There's no clear rationale for Europe prior to US filing. Diverting the energies to preparing European filing seems to me to be a clear admission that they can't get US approval. Pfizer for Viagra hasn't even bothered with much in Europe yet and look at the success they've had. If Vasomax hopes to beat Viagra to the punch in Europe they'll find what they found in Mexico. People will buy Viagra, which is known and has US approval, and not Vasomax, which is unknown and not even filed for approval. Linda